Large molecule therapeutics

null

Large molecule therapeutics

Laxai Life Sciences has successfully created a portfolio of biosimilars based on its proprietary platform technology. Laxai technology is based on novel vector designing and cell line development which can significantly lead to higher yields of product. Currently, Trastuzumab, Bevacizumab, Adalimumab and Filgrastim are in adavanced stage of development. Furthermore, Laxai plans to increase its spectrum of biosimilars in the area of oncology and auto-immune disorder.